Cantor Fitzgerald reiterates Aclaris Therapeutics stock rating

Aclaris Therapeutics, Inc. (ACRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update ​ - Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing -

NIO reported 4,165 battery swap stations and 5,376 charging stations in China, with 86.7% of energy delivered to non-NIO vehicles. The company aims to add 1,000 swap stations this year, with Geely Holding Group investing $2.4B in NIO Power. Onvo, a partner brand, has launched new models and expanded service centers. Retail investors on Stocktwits expressed bullish sentiment, with NIO shares down 31% YTD.

Equinor discovered gas at the Gullfaks field, which could sustain production. The well was drilled as part of a production well project. Equinor, Petoro, and OMV hold the license.

Dan Ives, a partner at Yorkville Ives, named Nvidia, Microsoft, Palantir, Apple, and CrowdStrike as his top tech stock picks for 2027. He highlighted a $4 trillion AI spending wave and set price targets: Nvidia ($300), Microsoft ($615), Palantir ($250), Apple ($400), and CrowdStrike ($335). The stocks have varied performance in 2026, with CrowdStrike up 126.50% and others showing modest gains.

Lululemon Athletica (LULU) has appointed Maggie Gauger as President and Chief Product Officer and Joseph Godsey as Chief Operating Officer. The changes are part of a broader leadership shake-up, with several senior executives departing. Analysts expect stable earnings of about US$1.4b and modestly lower profit margins around 12.4% over the next few years.

Goldman Sachs upgraded Rocket Pharmaceuticals (RCKT) to Neutral, raising its price target to $4.00. The company reported positive Phase 1 and Phase 2 results for RP-A501 in Danon disease, with FDA alignment on pivotal trial design. Rocket secured a $150M credit facility to fund operations until Q3 2028. Analysts have mixed views on the stock's potential.